Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$86.72 USD
-0.64 (-0.73%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $86.73 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$86.72 USD
-0.64 (-0.73%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $86.73 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
Zacks News
Gilead's (GILD) HCV Drug Application Accepted in the EU
by Zacks Equity Research
Gilead Sciences, Inc. (GILD) announced that the CHMP has adopted a positive opinion on the company's application for HCV drug Vosevi.
AbbVie's HCV Combo Drug Gets Positive CHMP Opinion in EU
by Zacks Equity Research
AbbVie Inc. (ABBV) announced that the CHMP of the EMA has recommended marketing approval of its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P).
Stock Market News for June 23, 2017
by Zacks Equity Research
The Nasdaq finished in the green for consecutive sessions on Thursday, boosted primarily by gain in health care shares
How to Find the Best Value Stocks
by Tracey Ryniec
A great value stock isn't just a cheap stock. Tracey uses a "secret sauce" to find the hidden gems among the cheap stocks.
Biotech Stock Roundup: Clovis Soars on Rubraca Data, Seattle Hit by Study Halt
by Arpita Dutt
Key highlights in the biotech sector include positive data on Clovis' (CLVS) PARP inhibitor, Rubraca.
Gilead's (GILD) HBV Drug Vemlidy Receives Approval in Canada
by Zacks Equity Research
Health Canada granted a Notice of Compliance (NOC) for Vemlidy 25mg tablets, a once-daily treatment for adults with chronic HBV infection with compensated liver disease.
Is Gilead Sciences a Great Stock for Value Investors?
by Zacks Equity Research
Let's see if Gilead Sciences Inc. (GILD) stock is a good choice for value-oriented investors right now from multiple angles.
Epizyme Provides Positive Interim Data on EZH2 Inhibitor
by Zacks Equity Research
Epizyme, Inc. (EPZM) announced positive interim data from an ongoing phase II study evaluating pipeline candidate tazemetostat as a monotherapy in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma
Biotech Stock Roundup: Management Changes at Biogen, Alexion, GILD Files HIV Drug
by Arpita Dutt
Key highlights in the biotech sector include management changes for Biogen (BIIB) and Alexion as well as a regulatory filing for Gilead's HIV regimen.
Gilead (GILD) Submits NDA for HIV Combination Therapy Regimen
by Zacks Equity Research
Gilead Sciences, Inc. (GILD) announced that it has submitted a NDA to the FDA for an investigational HIV combination therapy regimen.
The Zacks Analyst Blog Highlights: Gilead, BP, Dow Chemical, America Movil and MetLife
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead, BP, Dow Chemical, America Movil and MetLife
Top Stock Reports for Gilead, BP & Dow Chemical
by Sheraz Mian
Today's Research Daily features new research reports on 17 major stocks, including Gilead (GILD), BP (BP), and Dow Chemical (DOW).
Why Is Gilead Sciences (GILD) Down 3.5% Since the Last Earnings Report?
by Zacks Equity Research
Gilead Sciences (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Gilead Single Tablet Regiment for HIV Good in Phase III
by Zacks Equity Research
Gilead Sciences, Inc. (GILD) reported positive results on four phase III studies evaluating bictegravir in combination with FTC/TAF as a single tablet regimen for HIV infection.
Merck's HIV Drug Isentress Gets FDA Approval for Higher Dose
by Zacks Equity Research
Merck & Co., Inc. (MRK) recently announced that the FDA has approved Isentress HD, a new 1,200 mg once daily dose of its marketed drug Isentress (raltegravir), in combination with other anti-retroviral therapies.
Intercept's (ICPT) Liver Drug Ocaliva Approved in Canada
by Zacks Equity Research
Intercept Pharmaceuticals, Inc. (ICPT) announced that livver drug Ocaliva has obtained approval in Canada also.
Merck's HIV Drug Gets Positive CHMP Opinion for Higher Dose
by Zacks Equity Research
Merck & Co., Inc. (MRK) recently announced that the 600 mg film-coated formulation of its marketed drug, Isentress (raltegravir) in combination with other anti-retroviral therapies, has received positive opinion from CHMP.
Zacks Value Investor Highlights: Avis Budget Group, General Motors, Gilead Sciences, LGI Homes and Micron
by Zacks Equity Research
Zacks Value Investor Highlights: Avis Budget Group, General Motors, Gilead Sciences, LGI Homes and Micron
Value Stock or Value Trap?
by Tracey Ryniec
Tracey tells you how not to get fooled by value trap stocks on this week's podcast.
The Zacks Analyst Blog Highlights: Gilead, Dow Chemical, MetLife, Tesla and Emerson Electric
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead, Dow Chemical, MetLife, Tesla and Emerson Electric
Intercept (ICPT) Q1 Loss Narrower than Expected, Sales Beat
by Zacks Equity Research
Intercept Pharmaceuticals, Inc. (ICPT) posted a loss of $3.61 per share in the first quarter of 2017, narrower than the Zacks Consensus Estimate of a loss of $4.27.
Top Research Reports for Today: GILD, DOW, MET & More
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Gilead (GILD), Dow Chemical (DOW) and MetLife (MET).
Gilead Sciences Posts Mixed Q1 Results: ETFs in Focus
by Zacks Equity Research
Gilead beat Zacks EPS estimates, but missed on revenue, in the first quarter of 2017.
After Gilead Earnings, Buy These Biotech Stocks
by Madeleine Johnson
Shares of Gilead Sciences (GILD) are down about 2.6% in midday trading Wednesday after the biotech giant's first-quarter sales fell short of analyst estimates yesterday, leaving investors disappointed.
Gilead (GILD) Beats on Q1 Earnings, Revenues Miss Estimates
by Zacks Equity Research
Gilead Sciences, Inc.'s (GILD) first-quarter 2017 earnings (including the impact of stock-based compensation expenses) of $2.20 per share beat the Zacks Consensus Estimate of $2.18.